Pipeline Database
UB493
Search clinical-stage assets by therapeutic area, modality, target, indication, stage and territory — then inquire on any row that fits your brief.
UB493
IndicationsNon-small cell lung cancer; Colorectal cancer metastatic
ClinicalCN - NDA
TherapeuticsOncology
ModalitiesAntibody
Exclusive Summary
- Proven Equivalence: UB493 is a Bevacizumab biosimilar with Phase III clinical trials completed, featuring a head-to-head study against Roche's Avastin®.
- High-Demand Indications: Targets Non-Small Cell Lung Cancer (nsNSCLC) and Metastatic Colorectal Cancer, addressing substantial global oncology needs.
- Commercial Readiness: With clinical risks mitigated, the product is positioned for rapid registration and market entry (NDA-ready stage).
- Strategic Value: Offers a cost-effective biologic solution, ideal for partners seeking to capture market share in price-sensitive regions or expand oncology portfolios.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →